• Save
MD Paediatrics (Part 2) - Overview of Clinical Trials
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

MD Paediatrics (Part 2) - Overview of Clinical Trials

  • 457 views
Uploaded on

Brief overview of Clinical Trials

Brief overview of Clinical Trials

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
457
On Slideshare
457
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • Whether the drug reaches the cancerHow the drug behaves in the bodyHow cancer cells in the body respond to the drug
  • The safe dose rangeWhat the side effects areHow the body copes with the drugIf the treatment shrinks the cancer

Transcript

  • 1. Clinical Trials Overview
  • 2. Introduction • Sets of tests in medical research and drug development that generate safety and efficacy data for health intervention • i.e : information about adverse drug reactions and adverse effects of other treatments. e.g.: drugs, diagnostics, devices, therapy protocols
  • 3. Classification – Intervention • Observational • Interventional
  • 4. Classification - Purpose • Prevention trials – medicines, vitamins, vaccines, minerals, or lifestyle changes • Screening trials – best way to detect certain diseases or health conditions • Diagnostic trials – Find better tests or procedures for diagnosing • Treatment trials – experimental treatments, new combinations of drugs, new approaches to surgery or radiation therapy • Quality of life trials/supportive care trials • Compassionate use trials / expanded access trials – partially tested, unapproved therapeutics to a small number of patients who have no other realistic options • (U.S. N.I.H. classification)
  • 5. Phases – Drug development T0 T1
  • 6. Pre-Clinical • Nonhuman – Lab – Animal (Rats , Primates , etc) • Efficacy • Toxicity • Pharmacokinetics
  • 7. Phases… • Phase 0: Pharmacodynamics and Pharmacokinetics • Phase 1: Screening for safety • Phase 2: efficacy of the drug, usually against a placebo • Phase 3: Final confirmation of safety and efficacy • Phase 4: Post Market Surveillance • Phase 5: Translational Research (Meta Analysis)
  • 8. Phase 0 • First in Human Studies (FIH) /Proof of concept studies (POC) • Healthy subjects (10-15) • Single sub therapeutic dose (human microdosing studies) • Preliminary Pharmacodynamics & Phamacokinetics • Usually skipped (asses with Phase 01)
  • 9. Phase 1 • Volunteers(Healthy and Unhealthy) (20-80) • 1st stage of testing human subjects – Safety (Pharmacovigillance ) – Tolerance – Pharmacodynamics and Pharmacokinetics • Safe dosage • Half life • Types – Single ascending dose studies – Multiple ascending dose studies – Food effect assements • Therapeutic misconception
  • 10. Phase 2 • Phase 2A (IIA) – Assess dosing requirements • Phase 2B (IIB) – Study efficacy • Study Design – Case Series ,RCT • 100 -300 subjects
  • 11. Phase 3 • Compare new treatments with the best currently available treatment – Confirms its effectiveness – Monitor side effects • Randomized controlled multicenter trials • Drug licensing studies (Pre-marketing Phase) • Large study groups (300- 3000 subjects)
  • 12. Phase 4 • Postmerketing Surveillance • Safety Surveillance • Rare or long-term adverse effects over a much larger patient population • Harmful effects discovered by Phase IV trials may result in a drug being no longer sold, or restricted to certain uses – Eg: Roficoxib
  • 13. Phase 5 • Comparative effectiveness research and community-based research
  • 14. THANK YOU